ANO1 Gene-Knockout Mouse Model for Schizophrenia Research
Solution Overview
Problem
Current schizophrenia animal models are inadequate for studying molecular/genetic mechanisms and validating therapeutic agents, as they do not accurately replicate the complex symptoms of schizophrenia, and there is a lack of understanding about the correlation between the ANO1 gene and schizophrenia.
Innovation Solution
A mouse model is developed where the ANO1 gene is specifically knocked out in cholinergic neurons of the medial habenula, using a Cre/Lox genetic system, allowing for the creation of a novel schizophrenia animal model that exhibits positive, negative, and cognitive symptoms, and a method for preparing and using this model to screen therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional schizophrenia animal models are used, then basic research can be conducted, but the models do not accurately replicate complex schizophrenia symptoms and lack utility for validating therapeutic agents
Solution Approach 1:
The invention segments the ANO1 gene knockout to occur specifically in cholinergic neurons of the medial habenula, rather than system-wide knockout. This targeted segmentation creates a more physiologically relevant model that replicates schizophrenia symptoms while maintaining normal function in other brain regions, thereby improving both symptom accuracy and therapeutic validation utility.
Solution Approach 2:
The invention applies local quality by creating region-specific gene knockout in the medial habenula cholinergic neurons. This localized genetic modification produces schizophrenia-like symptoms without affecting other brain regions, making the model more reliable for symptom replication while preserving adaptability for therapeutic agent validation through controlled experimental conditions.
2Measurement precision
If transgenic animal models are developed to study specific genes, then molecular mechanisms can be investigated, but the complexity of schizophrenia pathogenesis cannot be fully captured
Solution Approach 1:
The invention segments the genetic modification to affect only specific cell types (cholinergic neurons) in a specific brain region (medial habenula), allowing precise investigation of ANO1 gene function while capturing the complex pathogenesis of schizophrenia through localized neural circuit disruption rather than system-wide effects.
Solution Approach 2:
The invention uses Cre-recombinase as an intermediary mechanism to achieve cell-type-specific gene knockout. This intermediary system allows precise control of ANO1 gene inactivation in cholinergic neurons, enabling molecular mechanism studies while the resulting behavioral phenotypes capture the complexity of schizophrenia through indirect neural circuit effects.
3Quantity of substance
If population studies are conducted to research environmental factors, then real-world data can be obtained, but accurate results are difficult to obtain due to costs and research subject limits
Solution Approach 1:
The invention creates a controlled animal model copy of schizophrenia pathogenesis, allowing research on environmental factors and gene-environment interactions without the limitations of human population studies. This model copy enables obtaining accurate results with smaller sample sizes and reduced time/cost while maintaining statistical power through controlled experimental conditions.
Data Source
AI summary
The present invention relates to: A schizophrenia animal model wherein the model is a mouse in which an anoctamin 1 (ANO1) gene is knocked out in cholinergic neurons of a medial habenula; and a preparation method therefor and the like. The schizophrenia animal model according to the present invention targets the medial habenula which is brain tissue playing a major role in the pathogenesis of schizophrenia, and it has been confirmed that when the ANO1 gene is specifically knocked out in the cholinergic neurons of the medial habenula, positive, negative and cognitive symptoms of schizophrenia are observed, thereby confirming that schizophrenia has been induced. Therefore, the animal model of the present invention is expected to be effectively useful in schizophrenia pathogenesis research and therapeutic agent development and screening.